Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned

CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB

Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w

– On track to also complete enrollment in the Seabreeze STAT COPD study this month –– Expect to repo

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to rep

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Ana

Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB)

Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart p

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNT

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Conne

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed th

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned ba

Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phas

The independent DMC reviewed interim data based on a pre-specified analysis of treatment failure at

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.27) per share which beat the

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or CO

BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and main

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Upda

– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pu

– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, w

Funding from new and existing investors extends anticipated cash runway into the second half of 2027

– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, w

– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pu

Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have ear

Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a cli

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Co

Connect Biopharma (NASDAQ: CNTB) CEO Barry Quart told investors at Oppenheimer's 36th Annual Healthc

BML Capital Management LLC cut its stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Con

– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potenti

Lake Street analyst Thomas Flaten initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) wit

BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and main

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.31) per share which missed th

BTIG analyst Julian Harrison initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a B

– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w